Tamura K - Search Results

1

Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).

Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: tamura k. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.

2

Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.

Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M, Masutomi K, Yoshida T, Fujiwara Y, Tamura K. Yunokawa M, et al. Among authors: tamura k. Cancer Sci. 2012 Sep;103(9):1665-71. doi: 10.1111/j.1349-7006.2012.02359.x. Epub 2012 Aug 1. Cancer Sci. 2012. PMID: 22703543 Free PMC article.

3

A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer.

Yunokawa M, Katsumata N, Yamamoto H, Kodaira M, Yonemori K, Shimizu C, Ando M, Tamura K, Fujiwara Y. Yunokawa M, et al. Among authors: tamura k. Cancer Chemother Pharmacol. 2013 May;71(5):1369-74. doi: 10.1007/s00280-013-2137-6. Epub 2013 Apr 5. Cancer Chemother Pharmacol. 2013. PMID: 23558943 Clinical Trial.

4

64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.

Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, Honda N, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Hasegawa K, Kanayama Y, Nozaki S, Kinoshita T, Wada Y, Tazawa S, Takahashi K, Watanabe Y, Fujiwara Y. Tamura K, et al. J Nucl Med. 2013 Nov;54(11):1869-75. doi: 10.2967/jnumed.112.118612. Epub 2013 Sep 12. J Nucl Med. 2013. PMID: 24029656 Free article.

5

Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.

Yamamoto H, Ando M, Aogi K, Iwata H, Tamura K, Yonemori K, Shimizu C, Hara F, Takabatake D, Hattori M, Asakawa T, Fujiwara Y. Yamamoto H, et al. Among authors: tamura k. Jpn J Clin Oncol. 2015 Jan;45(1):12-8. doi: 10.1093/jjco/hyu160. Epub 2014 Oct 20. Jpn J Clin Oncol. 2015. PMID: 25332421 Clinical Trial.

6

Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab.

Shimizu C, Mogushi K, Morioka MS, Yamamoto H, Tamura K, Fujiwara Y, Tanaka H. Shimizu C, et al. Among authors: tamura k. Breast Cancer. 2016 Jul;23(4):624-32. doi: 10.1007/s12282-015-0614-y. Epub 2015 May 12. Breast Cancer. 2016. PMID: 25962696

7

Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204.

Hojo T, Masuda N, Mizutani T, Shibata T, Kinoshita T, Tamura K, Hara F, Fujisawa T, Inoue K, Saji S, Nakamura K, Fukuda H, Iwata H. Hojo T, et al. Among authors: tamura k. Jpn J Clin Oncol. 2015 Oct;45(10):983-6. doi: 10.1093/jjco/hyv110. Epub 2015 Aug 5. Jpn J Clin Oncol. 2015. PMID: 26246481 Clinical Trial.

8

Novel combination of serum microRNA for detecting breast cancer in the early stage.

Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S, Shimizu C, Fujiwara Y, Kinoshita T, Tamura K, Ochiya T. Shimomura A, et al. Among authors: tamura k. Cancer Sci. 2016 Mar;107(3):326-34. doi: 10.1111/cas.12880. Epub 2016 Mar 4. Cancer Sci. 2016. PMID: 26749252 Free PMC article.

9

Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients.

Tamura K, Mukai H, Naito Y, Yonemori K, Kodaira M, Tanabe Y, Yamamoto N, Osera S, Sasaki M, Mori Y, Hashigaki S, Nagasawa T, Umeyama Y, Yoshino T. Tamura K, et al. Cancer Sci. 2016 Jun;107(6):755-63. doi: 10.1111/cas.12932. Epub 2016 May 11. Cancer Sci. 2016. PMID: 26991823 Free PMC article. Clinical Trial.

10

Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.

Ono M, Tsuda H, Yoshida M, Shimizu C, Kinoshita T, Tamura K. Ono M, et al. Among authors: tamura k. Clin Breast Cancer. 2017 Feb;17(1):41-47. doi: 10.1016/j.clbc.2016.06.012. Epub 2016 Jun 25. Clin Breast Cancer. 2017. PMID: 27477822 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,283 results

Search Page